This is also why GHK-Cu appears frequently in longevity-adjacent research alongside other compounds studied for age-related cellular changes, since a quantifiable, age-correlated decline gives researchers a concrete variable to test against rather than a purely theoretical one
New England Journal of Medicine (2025) The REDEFINE 2 Phase 3 trial evaluated CagriSema in 1,206 adults with overweight or obesity and type 2 diabetes in a 68-week, double-blind, placebo-controlled design
Use morning and night
(2023): The team led by Loren Pickart expanded the transcriptomic analysis of GHK-Cu's effect on human fibroblasts
Keep lyophilised vials away from light and moisture
Jonathan Berg, [email protected] Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers